Please login to the form below

Not currently logged in
Email:
Password:

Biogen buys into Rodin's Alzheimer's candidate

And may acquire the epigenetics-focused Massachusetts firm
Biogen Idec building

Biogen has signed a deal with Atlas Venture-backed Rodin Therapeutics that could result in the acquisition of the Alzheimer's disease-focused company.

Massachusetts-based Rodin is focusing on the development of small-molecule drugs for Alzheimer's that work via epigenetics, modulating cellular processes that result in gene expression being switched on or off.

The company's lead candidate is an inhibitor of histone deacetylase 2 (HDAC2), which is known to be upregulated in the brains of Alzheimer's patients and is thought to suppress normal neuronal function. The compound has not yet started clinical trials but is expected to do so within the next two to three years.

Biogen and Atlas are stumping up $17m to help Rodin advance its candidate into the clinical testing phase, and Biogen has also taken an option to buy Rodin outright for $485m.

Rodin's pipeline would complement Biogen's own activities in Alzheimer's, which include the development of aducanumab (BIIB037), which caused a stir last year after data from a clinical trial showed it could improve cognition as well as reduce the characteristic amyloid plaques seen in the brains of patients with mild disease.

Biogen said at the time that after multiple clinical failures for other compounds, this was the first evidence that an amyloid-targeting drug had shown an effect on cognition, although treatment with aducanumab was also associated with a troublesome side effect at its highest dose (10mg).

As this was also the most effective dose clinically, Biogen subsequently tested a 6mg dose in the hope of preserving activity while avoiding toxicity, but this study failed to meet its objectives at an interim stage.

Biogen has its own research programme in neuronal epigenetic research, according to Samantha Budd Haeberlein, Biogen's vice president of clinical development.

"Our investment in Rodin fits perfectly into our mission to bring innovative therapies to people with neurodegenerative disease and few treatment options," Haeberlein said.

Aside from Alzheimer's disease, Rodin's epigenetic modulators are also thought to have potential in other neurological conditions including Parkinson's disease, cognitive impairment in schizophrenia and post-traumatic stress disorder (PTSD).

Article by
Phil Taylor

8th January 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
TVF Communications

At TVF we do things a bit differently – our in-house design and development teams work directly alongside our commercial...

Latest intelligence

Blog_icon_understanding-the-adoption-ladder-in-closed-loop-marketing.png
Flexible content checklist – five questions to ask
To ensure that your content gets used by local markets and has a real impact, consider these questions when commissioning or developing core materials....
Experience design of physical spaces: a human-centred approach
Anna Tamasi from Blue Latitude Health highlights the key considerations and best practices for spatial design from a user experience design perspective....
Stronger together
A patient-focused strategy is high on the agenda, with a top-down approach favoured by industry leaders...

Infographics